ISDA: 9J7K

Deposition Date 2024-08-19

Release Date 2025-07-23

Last Version Date 2025-09-24

Entry Detail

PDB ID:

9J7K

Keywords:

VIRUS

Title:

Structure of AAV8 in the complex of AAV8 with its receptor

Biological Source:

Source Organism(s):

Adeno-associated virus - 8 (Taxon ID: 202813)

Expression System(s):

Homo sapiens

Method Details:

Experimental Method:

ELECTRON MICROSCOPY

Resolution:

2.32 Å

Aggregation State:

PARTICLE

Reconstruction Method:

SINGLE PARTICLE

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Capsid protein
Chain IDs:A (auth: 1), B (auth: A), C (auth: B), D (auth: C), E (auth: D), F (auth: E), G (auth: d), H (auth: i), I (auth: n), J (auth: s), K (auth: x), L (auth: 3), M (auth: e), N (auth: j), O (auth: o), P (auth: t), Q (auth: y), R (auth: 4), S (auth: f), T (auth: k), U (auth: p), V (auth: u), W (auth: z), X (auth: 5), Y (auth: g), Z (auth: l), AA (auth: q), BA (auth: v), CA (auth: 0), DA (auth: 6), EA (auth: h), FA (auth: m), GA (auth: r), HA (auth: w), IA (auth: 2), JA (auth: 7), KA (auth: F), LA (auth: J), MA (auth: N), NA (auth: R), OA (auth: V), PA (auth: Z), QA (auth: G), RA (auth: K), SA (auth: O), TA (auth: S), UA (auth: W), VA (auth: a), WA (auth: H), XA (auth: L), YA (auth: P), ZA (auth: T), AB (auth: X), BB (auth: b), CB (auth: I), DB (auth: M), EB (auth: Q), FB (auth: U), GB (auth: Y), HB (auth: c)
Chain Length:738
Number of Molecules:60
Biological Source:Adeno-associated virus - 8

UniProt ID:Q8JQF8 Pfam ID:PF00740, PF08398

Ligand Molecules

Primary Citation

An alternate receptor for adeno-associated viruses.

Dhungel, B.P, Xu, H, Nagarajah, R, Vitale, J, Wong, A.C.H, Gokal, D, Feng, Y, Tabar, M.S, Metierre, C, Parsania, C, Song, X, Wang, G, Su, X.D, Bailey, C.G, Rasko, J.E.J.Show

Cell 188 4924 ? (2025)

PMID: 40664211 DOI: 10.1016/j.cell.2025.06.026

Abstact

Systemic gene therapy using adeno-associated virus (AAV) vectors is approved for the treatment of several genetic disorders, but challenges and toxicities associated with high vector doses remain. We report an alternate receptor for AAV (AAVR2, carboxypeptidase D [CPD]), which is distinct from the multi-serotype AAV receptor (AAVR). AAVR2 enables the transduction of clade E AAVs, including AAV8, and determines an exclusive AAVR-independent transduction pathway for AAV11 and AAV12. We characterized direct binding between the AAV8 capsid and AAVR2 by cryo-electron microscopy (cryo-EM) and identified contact residues. We observed that AAV8 directly binds to the carboxypeptidase-like domain 1 of AAVR2 via its variable region VIII and demonstrated that AAV capsids that lack AAVR2 binding can be bioengineered to engage with AAVR2. Finally, we overexpressed a minimal functional AAVR2 to enhance AAV transduction in vivo. Our study provides insights into AAV biology and clinically deployable solutions to reduce dose-related toxicities associated with AAV vectors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form